Human papillomavirus is a risk factor for vulvar cancer, whereas human papillomavirus-negative late onset vulvar carcinoma is associated with the dermatologic condition, lichen sclerosus. Human papillomavirus E6 protein targets TP53 for degradation and by inference it has been assumed that human papillomavirus-negative vulvar cancer is dependent upon the acquisition of p53 somatic mutations and subsequent allelic loss. To investigate this, TP53 expression, loss of heterozygosity, and p53 genomic sequence were examined in 29 cases of human papillomavirus-negative vulvar carcinoma with adjacent lichen sclerosus. We examined 37 cases of lichen sclerosus without vulvar carcinoma, 10 cases of nongenital lichen sclerosus, and 12 cases of normal vulvar epithelium served as controls. TP53 was evident in 72% of vulvar carcinoma, 48% in epithelium adjacent to vulvar carcinoma, but was minimal in normal samples. When lichen sclerosus cases were selected to exclude samples with absolutely no TP53 expression through probable failed antigen retrieval or homozygous p53 loss the number of epithelial cells expressing TP53 increased progressively from nongenital lichen sclerosus to lichen sclerosus without vulvar carcinoma, then to lichen sclerosus with vulvar carcinoma (po0.0001). These data suggest elevated TP53 is a feature of vulvar lichen sclerosus. Seventy-four percent of vulvar carcinoma had chromosome 17p-linked loss of heterozygosity, whereas 47% of adjacent lichen sclerosus featured loss of heterozygosity, but only 31% of vulvar carcinoma had p53 mutations, a frequency less than reported previously. Seven percent of adjacent lichen sclerosus had mutations, showing for the ¢rst time the presence of an identical mutation to the matched vulvar carcinoma. These data, however, implicate p53 mutations as a later event in vulvar carcinoma and in marked contrast to the original expectation, our loss of heterozygosity data are consistent with loss of another locus (not p53) on 17p operating as a tumor suppressor in lichen sclerosus destined to develop vulvar carcinoma. Key words: lichen sclerosus/loss of heterozygosity/mutation analysis/p53/tumor suppressor gene/vulvar carcinoma. J Invest Dermatol 119: 1027^1033, 2002 
Human papillomavirus is a risk factor for vulvar cancer, whereas human papillomavirus-negative late onset vulvar carcinoma is associated with the dermatologic condition, lichen sclerosus. Human papillomavirus E6 protein targets TP53 for degradation and by inference it has been assumed that human papillomavirus-negative vulvar cancer is dependent upon the acquisition of p53 somatic mutations and subsequent allelic loss. To investigate this, TP53 expression, loss of heterozygosity, and p53 genomic sequence were examined in 29 cases of human papillomavirus-negative vulvar carcinoma with adjacent lichen sclerosus. We examined 37 cases of lichen sclerosus without vulvar carcinoma, 10 cases of nongenital lichen sclerosus, and 12 cases of normal vulvar epithelium served as controls. TP53 was evident in 72% of vulvar carcinoma, 48% in epithelium adjacent to vulvar carcinoma, but was minimal in normal samples. When lichen sclerosus cases were selected to exclude samples with absolutely no TP53 expression through probable failed antigen retrieval or homozygous p53 loss the number of epithelial cells expressing TP53 increased progressively from nongenital lichen sclerosus to lichen sclerosus without vulvar carcinoma, then to lichen sclerosus with vulvar carcinoma (po0.0001). These data suggest elevated TP53 is a feature of vulvar lichen sclerosus. Seventy-four percent of vulvar carcinoma had chromosome 17p-linked loss of heterozygosity, whereas 47% of adjacent lichen sclerosus featured loss of heterozygosity, but only 31% of vulvar carcinoma had p53 mutations, a frequency less than reported previously. Seven percent of adjacent lichen sclerosus had mutations, showing for the ¢rst time the presence of an identical mutation to the matched vulvar carcinoma. These data, however, implicate p53 mutations as a later event in vulvar carcinoma and in marked contrast to the original expectation, our loss of heterozygosity data are consistent with loss of another locus (not p53) on 17p operating as a tumor suppressor in lichen sclerosus destined to develop vulvar carcinoma. Key words: lichen sclerosus/loss of heterozygosity/mutation analysis/p53/tumor suppressor gene/vulvar carcinoma. J Invest Dermatol 119: 1027^1033, 2002 V ulvar squamous cell carcinoma development follows two pathways. One strongly associated with human papillomavirus (HPV) serotypes 16 and 18, the other occurring over a longer time frame, in the context of the dermatologic disease lichen sclerosus (LS). LS documented as an adjacent epithelial lesion to vulvar carcinoma (VC) ranges from 9% to 100% (Leibowitch et al, 1990; Toki et al, 1991; Hording et al, 1994; Ridley, 1994) . Thus the relevance of LS to VC is controversial. For decades it has been hypothesized that LS is a predisposing condition to VC (Carlson et al, 1998) . Although LS can develop all over the body, it is only on the vulva, penis, and perineum that it is associated with cancer (Weber et al, 1987; Pride et al, 1993; Ridley, 1994) .
The HPV E6 protein functionally inactivates the tumor suppressor gene protein, TP53, ablating its activity as a cell-cycle regulator and transcriptional activator in DNA damage, repair responses, and apoptosis (Thomas et al, 1999) . Thus it has been presumed that E6 -mediated TP53 degradation obviates the selective pressure for p53 mutagenesis in HPV-positive cancers as these tumors rarely show p53 mutations (Crook et al, 1992; Fujita et al, 1992; Helland et al, 1993; Kessis et al, 1993; Park et al, 1994) . This is also the case for VC. Previous studies have reported 22^75% of HPV-negative VC harbor p53 mutations (Lee et al, 1994; MildeLangosch et al, 1995; Pilotti et al, 1995; Kim et al, 1996; Sliutz et al, 1997) . These observations suggest that p53 somatic mutations accumulate over time in HPV-negative VC similar to the general trend in other epithelial tumors (Hollstein et al, 1991; Greenblatt et al, 1994) . It is unclear, however, whether the described precursor lesions adjacent to HPV-negative VC arise or progress to tumors in a p53 mutation-dependent manner.
Generally, the detection of TP53 expression is thought to be indicative of either induced or transient stabilization of wild-type protein, or more commonly a mutation leading to more stable mutant TP53 (May et al, 1999) . Increased TP53 expression in LS of the vulva without VC compared with nongenital LS has been reported suggesting that there may be an anatomical di¡erence in the two subtypes of LS or a di¡erence in the degree of carcinogenic stimulation (Soini et al, 1994) . In this study we investigated the p53 status in LS as an indicator of a cellular stress response and/or ''preneoplastic'' change. We have brought together cases of documented HPV-negative VC with adjacent LS, LS of the vulva without VC, nongenital LS, and normal vulvar epithelium, excluding the possibility that TP53 expression was being altered by HPV. For the ¢rst time the status of the p53 gene was assessed simultaneously using three criteria: immunohistochemistry, loss of heterozygosity (LOH), and direct sequencing to investigate molecular changes in VC and its adjacent epithelial components in comparison with LS of the vulva in the absence of cancer and in nongenital LS.
This systematic and comprehensive study of p53 status has highlighted the strong expression of wild-type TP53 in LS of the vulva but not in nongenital LS or normal vulvar epithelium. The data support the suggestion that the overexpression of wildtype TP53 is an important feature of LS of the vulva distinguishing it from LS elsewhere and certainly normal skin. Although LOH and p53 mutations are frequent in VC, our data support the view that p53 mutagenesis is involved in the later stages of vulvar carcinogenesis. Furthermore, it is proposed that the molecular changes associated with progression of VC from associated LS uncommonly involve p53 mutation but rather our LOH data suggest another tumor suppressor gene on chromosome 17p may be important.
MATERIALS AND METHODS
Clinical specimens and histologic assessment Twenty-nine cases of invasive vulvar squamous cell carcinoma and with adjacent LS. Forty-four cases of LS of the vulvar without carcinoma collected from and diagnosed at the Mercy Hospital for Women and Royal Women's Hospital between 1985 and 1997 were selected. Ten cases of nongenital LS on the body diagnosed at Dorevitch Pathology (Melbourne) were also included. Twelve cases of normal vulvar epithelium and three cases of nongenital normal skin collected from the Mercy Hospital for Women were used as controls. Each VC case was identi¢ed by histologic criteria as described previously (Scurry et al, 1997) on the basis of: (i) presence of adjacent LS; (ii) unequivocal presence of VC; and (iii) su⁄cient archival material for molecular and immunohistochemical analysis. Epithelial skin adjacent to the tumor was classi¢ed as normal, LS, squamous cell hyperplasia (SCH), di¡erentiated vulvar intraepithelial neoplasia (DVIN), or undi¡erentiated vulvar intraepithelial neoplasia. HPV typing of a larger series of VC cases, including the series reported here, was performed previously (Scurry et al, 1998) . In this study all HPV-positive cases detected using polymerase chain reaction (PCR) primers to genotypes 16, 18, or pan-HPV were excluded.
Immunohistochemistry Analysis of TP53 and p21
CIP-1/WAF-1 expression was carried out using mouse anti-TP53 Ab6 (Calibochem (San Diego, CA)) and mouse anti-p21 Ab3 (Neomarkers (Fremont, CA)) antibodies following antigen retrieval. Three micrometer sections were cut from the formalin-¢xed para⁄n-embedded tissue blocks and collected on 3 -aminopropyltriethoxy-silane (Sigma (Sydney, NSW, Australia)) treated slides. Sections were dewaxed in xylene and rehydrated in graded methanol. Endogenous peroxidases were blocked with 0.9% H 2 O 2 / methanol for 15 min, then hydrated. Antigen retrieval was performed using boiling 10 mM citrate bu¡er (pH 6) incubated for 20 min in a microwave oven at low power, and then allowed to cool. Sections were washed twice in Tris-bu¡ered saline (TBS: 0.25 M NaCl, 25 mM Tris pH 7.6). Nonspeci¢c binding was blocked with 2% fetal bovine serum (P.A.Biologicals (Havelock North, New Zealand))/TBS for 30 min. Sections were incubated with the primary antibody in 2% fetal bovine serum/TBS (1 : 50 dilution) for 60 min, washed with TBS (5 min), then incubated with goat anti-mouse horseradish peroxidase antibody (BioRad (Hercules, CA); 1 : 200 dilution), in 2% fetal bovine serum/TBS for 30 min. Sections were then washed with TBS (5 min). Protein expression was visualized using 0.05% diaminobenzidine (Sigma) in TBS, the reaction was activated with 20 ml H 2 O 2 , sections were counter-stained with hematoxylin for 1 min, dehydrated in graded ethanol, cleared in xylene and mounted with DPX mounting solution (BDH (Merck, Kilsythe, Vic, Australia)) and cover-slipped. TP53 expression was scored per 100 basal cells as described previously (Tan et al, 1994) . Brie£y, 100 consecutive basal cells were identi¢ed and all cells above the basement membrane (epidermis) in this ¢eld were scored for TP53 expression. Three separate ¢elds were assessed and the average used in the determination of expression. Intensity of TP53 expression
Cases were considered negative if there was no evidence of p53 or p21 expression in the entire section. Three observers using reference slides with agreed straining intensities reviewed all sections.
DNA extraction Sections of 5 mm were cut from the formalin-¢xed para⁄n-embedded tissue blocks. Sections were dewaxed in xylene and rehydrated in graded ethanol, and then stained using hematoxylin and eosin. The VC and adjacent epithelium, vulvar LS without VC, and nongenital LS were microdissected using a micropapillary pipette (Sigma) attached to a micromanipulator (Nikon (Tokyo, Japan)) and visualized through an inverted microscope (Nikon). Hematoxylin and eosin stained sections in combination with the immunohistochemically stained sections were used to guide microdissection. The microdissected cells were collected in silicon-treated Eppendorf tubes. Protein was removed with Proteinase K digestion and the DNA precipitated with isopropanol and 300 mM sodium acetate in the presence of 20 mg of nuclease-free glycogen.
LOH These studies were performed using two p53 polymorphic markers, a pentanucleotide Alu sequence with an (AAAAT) 8 repeat (Cawkwell et al, 1994) and a dinucleotide (CA) 25 repeat (Jones and Nakamura, 1992) . Sense and anti-sense primers £anking the pentanucleotide and dinucleotide loci are as previously described (Jones and Nakamura, 1992; Cawkwell et al, 1994) . PCR were performed in 25 ml containing 0.5 mm of each forward primer (Bresatec (Adelaide, SA, Australia)) and 1.5 mm of reverse primer end-labeled with [g-32 P] adenosine triphosphate (3000 Ci per mol, 10 mCi per ml) (Dupont (Wilmington, DE)), 200 ml deoxyribonucleoside triphosphate (Promega (Annandale, NSW, Australia)), 2.5 mM MgCl 2 , 2.5 ml Â 10 PCR Bu¡er (Perkin Elmer (Boston, MA)), 0.25 mM spermidine, 1.2 mM Taq Start Antibody (Clontech), 0.88 ml Taq Start Antibody Dilution Bu¡er (Clontech (Palo Alto, CA)), 1 U Taq polymerase and 1^3 ng DNA.
Pentanucleotide marker PCR were performed after denaturation at 941C for 5 min, two cycles of denaturation at 951C for 30 s, annealing at 631C to 551C, at 21C intervals for 30 s and extension at 721C for 30 s, 32 cycles, including denaturation at 951C for 30 s, annealing at 551C for 30 s and extension at 721C for 30 s with a ¢nal extension at 721C for 10 min. Similarly, dinucleotide marker PCR was performed as described except annealing was performed at 681C to 601C. Denaturing bu¡er, 8 ml (20 mM ethylenediamine tetraacetic acid, 0.05% xylene cyanol, 0.05% bromophenol blue, and 95% formamide) was added to 5 ml of the PCR product. Samples were heat denatured and immediately cooled on ice. The samples were loaded on to a 6% polyacrylamide/Tris-borateethylenediamine tetraacetic acid electrophoresis bu¡er gel. Upon completion of electrophoresis the gel was dried and exposed to Kodak Biomax-MR ¢lm overnight. LOH was scored by visual detection as a minimum of 50% reduction in band intensity. p53 mutation analysis Primers for p53 exons 5, 6, 7, and 8 have been described previously (Brash et al, 1991) and PCR were performed essentially as described above with the following modi¢cations. Exons 5 and 6 PCR were performed at an initial denaturation of 941C for 5 min, then 32 cycles of: denaturation at 951C for 30 s, annealing at 661C to 581C (21C intervals for 30 s) and extension at 721C for 30 s and ¢nal extension at 721C for 10 min. Exon 8 PCR were also performed similarly except annealing was at 581C to 501C. PCR was performed for exon 7 following the same program as the pentanucleotide repeat in the LOH analysis. PCR products were analyzed on a 2% agarose gel. Primers and primer-dimers were removed from the PCR extended products with Wizardt PCR preps DNA puri¢cation System (Promega). Direct DNA sequencing of ampli¢ed PCR products using an internal primer (Bresatec) speci¢c for each exon was performed using the SequiThermt Cycle Sequencing Kit (Epicentre Technologies (Owens Cross Roads, AL)) and [a- . DNA sequences were analyzed on a 6% polyacrylamide/Tris-borateethylenediamine tetraacetic acid electrophoresis bu¡er sequencing gel. Autoradiography was performed overnight.
Statistical analyses To test whether TP53 expression increased from nongenital LS to LS of the vulva without VC to LS adjacent to VC, for each case, three microscopic ¢elds were chosen at random from the corresponding tissue. In three cases of LS of the vulva without VC, fewer than three ¢elds were taken due to insu⁄cient tissue. For each case, the average of the TP53 expression scores was obtained. The hypothesis was tested using nonparametric analysis of variance (one-sided JonckheereT erpstra test). The intensity score was dichotomized to 2 or more vs less than 2. To test the hypothesis that the intensity increased from nongenital LS to LS of the vulva without VC to LS adjacent to VC, a one-sided Cochran^Armitage test for trend for ordinal data based on the exact distribution was used. For each VC case, the intensity scores were documented in the tumor and its adjacent epithelium, where possible. The aim was to examine whether there was evidence for increasing TP53 intensity from the normal epithelium, to LS only, to LS coexistent with SCH/DVIN, to the tumor. As results from the same case may be correlated, the analysis was performed using a logistic regression model with distinguishable binomial random e¡ect (Collett, 1991) . A linear term was included in the model indicating the ranking of the type of tissue in terms of increasing neoplasia. The normal epithelium was given a rank of 1, LS had a rank or 2, LS coexistent with SCH/DVIN had a rank of 3 and the tumor had a rank of 4. A one-sided likelihood ratio test was used to test the signi¢cance of this term after removing it from the model. The deviance and the degrees of freedom associated with the model were examined for goodness of ¢t. A permutation test was used to determine whether the observed matching of mutations in VC and LS of the same case was consistent with chance. The test was carried out by considering all the possible permutations of results for the 29 VC mutation outcomes with the 29 mutation outcomes of LS. The p-value was the proportion of these permutations for which at least the observed number of matching mutations occurred.
All tests carried out, unless speci¢ed, were two-sided, and po0.05 was considered to be signi¢cant. No formal adjustments were made for multiple comparisons. The analyses were carried out using StatXact for Windows (version 4.0) and EGRET statistical package for Windows (version 2.0.1).
RESULTS
TP53 expression Twenty-nine tumor samples were classi¢ed into three groups: (i) tumor and adjacent components exhibiting TP53 expression (14 cases); (ii) expression restricted only to the tumor (seven cases); and (iii) tumor and adjacent components TP53 negative (eight cases). TP53 expression in the adjacent epithelium was largely localized to focal patches or clusters of epithelial cells mainly con¢ned to basal and parabasal layers and thus indicative of clonal heterogeneity (Fig 1A, panels 1 and 2 ). This compares with extensive TP53 staining in VC (Fig 1A,  panel 3) . Four of 14 VC cases had TP53 expression in apparently normal adjacent epithelium.
Sparse and weak TP53 basal expression was mainly seen in 37 of 44 LS of the vulvar without carcinoma specimens (Fig 1A,  panel 4) , whereas the nongenital LS cases, on average, had weaker expression ( Fig 1A, panel 5) . One LS case of the vulvar without carcinoma had markedly intense and extensive TP53 expression, including enlarged nuclei compared with the others in the study (Fig 1A, plate 6 ), highlighting it for further analysis (see below). No detectable TP53 expression was noted in 12 normal vulvar and three nongenital normal epithelium specimens.
To initiate our investigation into the status of the TP53 expressed in LS samples we examined the expression of p21/ WAF-1/CIP-1, a TP53 responsive gene. In two cases a clear relationship between the two genes expression was evident (Fig 1B) where the basal cell and epidermal expression coincided. Although, p21 expression extended beyond the basal layer in these examples (perhaps due to longer p21 half life compared with TP53), in general p21 expression in the basal layer of LS was uncommon and rarely were TP53 and p21 found in the same cells. Others have observed such discordant expression in normal and malignant tissues and most notably in mouse cells where both alleles of the p53 gene had been deleted (el-Deiry et al, 1995) . This suggested to us that the expression status of p21 is by itself unhelpful in determining whether the observed TP53 is a wild-type or mutant protein.
There was no evidence that TP53 expression increased from nongenital LS to LS of the vulva without VC to LS adjacent to VC (p ¼ 0.52) when all cases were included in the analysis. It should be noted, however, that only 48% of cases of LS found adjacent to VC exhibited any TP53 expression perhaps leading to a potential skewing of the distribution of the data (Fig 2A) . As p53 mutation can lead to the complete absence of detectable expression and absence of TP53 can be simply a function of failed antigen retrieval, we also examined these groups following the exclusion of all completely negative cases. That is, cases where not a single nucleus within three ¢elds stained positive for TP53 antigen. Consequently, 15 (52%) cases of LS found adjacent to VC and one (3%) case of nongenital LS were omitted from the analysis. Using these sampling criteria, there was strong evidence that TP53 expression increased from nongenital LS to LS of the vulva without VC to LS found adjacent to VC (po0.0001, Fig 2B) .
The intensity of TP53 expression was also documented in the VC cases and their adjacent epithelium (Table IA) . There was an increasing linear trend in intensity of TP53 expression from adjacent normal tissue to tissue with LS only to LS coexistent with SCH or DVIN to the tumor (po0.0001).
A comparison of intensity between all groups of LS was performed (Table IB) . Both groups of nongenital LS and LS without VC had no evidence of SCH or DVIN. Hence, in the group of LS adjacent to VC, the 25 cases with no evidence of SCH or DVIN were included for the comparison. Although there was a trend to more intense TP53 staining from nongenital LS to LS of the vulva with VC to LS adjacent to VC the di¡erence based upon the sample size was not signi¢cantly di¡erent (p ¼ 0.24). LOH p53 LOH was assessed using two polymorphic markers, where 19 of 29 were informative for at least one of the two polymorphic loci. Fourteen of 19 VC had LOH, where LOH was also detected in the adjacent components; ¢ve LS, and ¢ve LS superimposed with either SCH or DVIN (Fig 3) . No LOH was detected in LS without VC, and nongenital LS, where 28 of 37 and eight of 10, respectively, were informative for at least one of the two polymorphic loci tested. Therefore, the LOH analysis suggested allelic loss of the p53 gene in VC and its adjacent components.
p53 mutations DNA sequence analysis of the p53 gene in all VC cases and adjacent components focused upon the frequently reported hotspot regions, exons 5^8. In nine of 29 VC cases p53 mutations were observed in either the tumor, adjacent LS or in both (Table II) . Eight tumors had a detectable p53 mutation. An example of a p53 mutation in a VC case is shown in Fig 4(A) and, importantly, the presence of the same p53 mutation in LS and VC from the same patient that is absent in the normal tissue (Fig 4B) . Table II combines the three data sets highlighting the lack of association of LOH and p53 mutations in the presence of high TP53 expression in LS and VC. On a technical note we found that our initial set of mutational data revealed that approximately 49% of VC have p53 mutation; however, in some instances further replicate experiments failed to reproduce the original documented mutation. Di⁄culties in processing and sequencing para⁄n-derived DNA is notorious for p53 mutation detection (Williams et al, 1999) leading to false positive determinations. The reports of p53 mutations made here are based upon triplicates derived from three independent PCR. The consistency and accuracy of our direct sequencing techniques and the integrity of our DNA was supported by the continual reproducibility (triplicate independent PCR) of amino acid codon polymorphisms in the VC and adjacent epithelial lesions, and the absolute reproducibility of a documented p53 mutation (40 of 40 cloned and sequenced products following PCR) from a VC cell line, A431 (data not shown). Three cases had a detectable mutation in adjacent LS, two of which had matching mutations in the tumor. This association is highly statistically signi¢cant (p ¼ 0.007), whereas the remaining case had a mutation detected only in LS. The matching mutations in LS and the tumor are important for two reasons: these were the ¢rst reported cases of p53 mutations in LS and they suggest that the epithelial tumor cells arose from the same clone of cells with LS.
We did not detect p53 mutations in LS without VC even in one candidate case with markedly intense TP53 expression and aberrant nuclear morphology (Fig 1A, panel 6) . Furthermore, in all cases direct sequencing identi¢ed wild-type and mutant alleles present at the site of mutation suggesting that the wild-type allele had not been lost. These data suggest that selection for homozygous loss of the wild-type p53 is not a requisite for VC or perhaps that selection for LOH of another chromosome p17 locus underlies the apparent uncoupling of the LOH and mutation data.
DISCUSSION
The incidence of p53 mutations in late stage epithelial cancers is typically reported to be 50^70% (Hollstein et al, 1991) . This study has focused upon the possible role of p53 in early events in VC initiation and progression. The relationship between early onset VC and HPV infection implicates TP53 inactivation as an early event in this group of VC patients. Similarly, the frequent association between VC and the dermatologic condition LS in HPV-negative VC patients has led to the suggestion of a parallel role for p53 mutations in LS progression to VC. This study examined the p53 status of VC in the context of adjacent LS and found p53 mutations in VC can be observed in adjacent LS. p53 mutations and LOH, however, could not account for the high apparently wild-type TP53 expression observed in LS of the vulva.
The importance of HPV in tumor development became apparent from studies investigating the pathogenesis of cervical carcinoma. HPV 16 and 18 are most commonly found in cervical carcinoma (Vousden, 1989) and virally encoded E6 forms a complex with TP53 (Werness et al, 1990) . HPV-positive cervical carcinomas rarely show p53 mutations (Fujita et al, 1992; Kessis et al, 1993) . This led to the subsequent revelation that loss of wild-type p53 is important in the pathogenesis of HPV-negative cervical carcinoma. In the absence of HPV, tumor development is said to be reliant upon the loss of TP53 function through somatic mutations (Crook et al, 1991 (Crook et al, , 1992 . Indeed, mutations in the p53 gene have been reported in HPV-negative VC as they have been in numerous other human cancers (Hollstein et al, 1991; Greenblatt et al, 1994) .
Detection of mutant TP53 has been widely investigated in using immunohistochemistry on the basis that it is more stable 
and abundant than the wild-type protein; however, immunohistochemistry employing many of the anti-TP53 reagents do not discriminate between wild-type and mutant forms of TP53 (Battifora, 1994) , thus there is a need for caution when interpreting results. Expression of TP53 is minimal in most normal cells (MacGeoch et al, 1993; Battifora, 1994) , including cells of normal vulvar skin (Soini et al, 1994; Kagie et al, 1997; McConnell et al, 1997) and normal nongenital skin samples examined here. When we considered only cases where we were certain TP53 antigen retrieval was successful, we found a marked di¡erence in TP53 expression between nongenital LS compared with vulvar LS (po0.0001). This suggests that the di¡erent anatomical location of LS has consequences relevant to tumor development (McConnell et al, 1997) . TP53 expression arises when it is serving as the central mediator of the G1/S checkpoint in response to DNA damage (Leonard et al, 1995) and detectable TP53 expression was found in 97% of nongenital LS cases and in some cases a substantial proportion of cells expressed TP53. Therefore, although, LS is considered to be a non-neoplastic disease these results suggest that the accumulation of TP53 in LS in the absence of carcinoma is due to the overexpression of wild-type TP53. Thus wild-type TP53 overexpression may be a feature of this in£ammatory disease (Soini et al, 1994; Tan et al, 1994) . Others have recently reported that another component of the p53 pathway, mdm2, may be in£uencing wild-type TP53 expression (Carlson et al, 2001) ; however, we favor the view that the TP53 expression we have observed re£ects a stress response associated with in£ammation or carcinogenic insult and perhaps cell cycle arrest. In support of this view is an increase in expression in LS of the TP53 -target gene p21 (in some LS cases) the expression of which is associated with arrest; however, our data did not show a tight concordance between p21 and TP53 expression in all cases of LS or VC attesting to the complex nature of p21 regulation in normal and malignant tissues (el-Deiry et al, 1995) . Therefore, our ¢nding of TP53 expression in 72% VC cases was vastly in excess of the detection of p53 mutation. A similar situation has been reported where adjacent ''normal'' epidermis and basal cell carcinoma showed considerable divergence between TP53 expression and detectable p53 mutation (Ponten et al, 1997) .
The use of DNA microsatellites as markers of LOH on chromosome 17 has been investigated extensively in a variety of human tumors, including squamous cell carcinomas of the skin, where approximately 33% of squamous cell carcinomas have allelic loss of chromosome 17p (Quinn et al, 1994) . Seventy-four percent of VC cases informative for at least one of the two polymorphic loci had LOH at either p53 loci tested. In another study four of ¢ve of HPV-negative VC had LOH at chromosome 17p (Pinto et al, 1999) . To the best of knowledge our study is the ¢rst to demonstrate LOH in the VC precursor lesion LS. We detected nine cases of LS adjacent to VC with LOH. Very importantly, LOH was not detected in LS of the cancer-free vulvar or in nongenital LS, at best supporting the role of p53 loss as a mid (Carlson et al., 2001) to late event in vulvar cancer progression. Our ¢nding that VC cases had an identical p53 mutation in the adjacent LS for the ¢rst time shows molecular evidence for the progression from this condition to cancer. Although these data do not prove that LS progressed to VC, the association of an identical mutation in matching LS and VC from the same patient was highly signi¢cant (p ¼ 0.007) and, therefore, it is extremely unlikely that in these two cases, the VC did not arise from the adjacent LS.
Our ¢nding that LOH did not predict the presence of a mutation in p53 is in opposition to the traditional view that p53 mutation is frequently followed by the loss of the wild-type allele. There are two explanations for a lack of p53 mutations within these tumors: (i) mutations being harbored outside the sequences tested, and (ii) the loss of another gene on chromosome 17p as observed in other cancers (Chen et al, 1991; Cornelis et al, 1994; Swift et al, 1995; Grebe et al, 1997 ). Therefore we argue that p53 mutations arise at a later stage in VC development rather than acting as the driving force underlying vulvar carcinogenesis. The data are also most consistent with the loss of a tumor suppressor gene on chromosome 17p as an early event in the development of VC from LS. In circumstances where LOH and p53 mutations are clearly associated and very likely to be of etiologic importance the detection of p53 mutation precedes the apparent selection of LOH (Greenblatt et al, 1994; May et al, 1999) . Contrasting this scenario is the appearance of chromosome 17p LOH in LS before the emergence of p53 mutations in VC coupled to the observation that LOH of the mutant allele was commonly observed. This study presents evidence for chromosome 17p LOH in a premalignant dermatologic disease associated with this form of squamous cell carcinoma. This suggests an alternative pathway to that originally implicated by molecular studies based upon early onset HPV-positive VC.
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